Elanco Animal Health Incorporated (ELAN)
| Market Cap | 12.69B +71.3% |
| Revenue (ttm) | 4.89B +10.5% |
| Net Income | -242.00M |
| EPS | -0.49 |
| Shares Out | 499.45M |
| PE Ratio | n/a |
| Forward PE | 23.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,709,513 |
| Open | 25.25 |
| Previous Close | 24.91 |
| Day's Range | 25.14 - 25.63 |
| 52-Week Range | 13.39 - 27.72 |
| Beta | 1.69 |
| Analysts | Strong Buy |
| Price Target | 30.07 (+18.34%) |
| Earnings Date | Aug 5, 2026 |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ELAN stock is "Strong Buy." The 12-month stock price target is $30.07, which is an increase of 18.34% from the latest price.
News
Elanco price target raised to $26 from $23 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on Elanco (ELAN) to $26 from $23 and keeps an Equal Weight rating on the shares. U.S. vet practices are…
Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)
Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro: Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours...
Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct...
Elanco price target raised to $32 from $31 at TD Cowen
TD Cowen analyst Steve Scala raised the firm’s price target on Elanco (ELAN) to $32 from $31 and keeps a Buy rating on the shares. The firm said seven potential…
Elanco to launch Elanco Ventures for animal health innovation
Elanco (ELAN) Animal Health plans to establish Elanco Ventures, a dedicated corporate venture capital platform designed to support, invest and advance innovation in animal health. To be backed by a…
Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health
New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: E...
Elanco announces USDA approval of TruCan Ultra Lyme-L4
Elanco (ELAN) Animal Health announced the U.S. Department of Agriculture approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vacc...
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs
TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine...
Elanco CEO on rolling out New World screwworm vaccine: 'We're prepared'
Jeffrey Simmons, Elanco, joins 'Closing Bell Overtime' to talk producing a vaccine for the New World Screwworm infection in cattle in the U.S.
Confirmed screwworm case in Texas sends two biotech stocks higher
Options volume is surging for Zoetis as traders look for potential stock market winners in light of a screwworm case in Texas.
Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm
Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first conf...
New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to priorit...
Elanco Animal Health Transcript: 46th Annual William Blair Growth Stock Conference
The company is leveraging a robust innovation pipeline and diversified global presence to drive mid-single-digit revenue growth, high single-digit EBITDA, and over $1 billion in free cash flow through 2028. U.S. pet health is a key growth area, with new product launches and resilient consumer demand supporting strong financial guidance.
Elanco Animal Health Slides: 46th Annual William Blair Growth Stock Conference
Elanco Animal Health has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Elanco Animal Health Transcript: Stifel Jaws & Paws Conference 2026
The conference highlighted robust growth in animal health, driven by innovation in pet and farm segments, resilient pricing, and strong product launches like Zenrelia and Befrena. Strategic focus remains on operational efficiency, disciplined capital allocation, and a robust pipeline for future growth.
Elanco Animal Health Transcript: AGM 2026
The meeting highlighted strong 2025 results, with growth in both pet and farm animal segments and innovation driving $1.2 billion in revenue. All board nominees and proposals were approved, and the company outlined plans for new blockbuster products and continued margin improvement.
Elanco launches Befrena for canine allergic itch
Elanco (ELAN) announced the phased launch of Befrena – tirnovetmab -, a new anti-IL-31 monoclonal antibody injection for treatment of canine allergic and atopic dermatitis. Befrena expands Elanco’s de...
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of...
Elanco price target lowered to $23 from $24 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $23 from $24 and keeps an Equal Weight rating on the shares.
Elanco to Participate in Upcoming Investor Conferences
INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff ...
Elanco price target raised to $30 from $28 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Elanco (ELAN) to $30 from $28 and keeps an Overweight rating on the shares.
Elanco price target raised to $31 from $30 at Citi
Citi raised the firm’s price target on Elanco (ELAN) to $31 from $30 and keeps a Buy rating on the shares. The firm says the company reported a “clean beat-and-raise”…
Elanco reports Q1 adjusted EPS 40c, consensus 34c
Reports Q1 revenue $1.37B, consensus $1.28B. “Elanco’s (ELAN) strong first quarter results demonstrate the significant momentum of our innovation-led strategy,” said Jeff Simmons, President and CEO of...
'WE WILL BE PREPARED': Inside efforts to stop screwworm outbreak
Elanco Animal Health CEO Jeff Simmons discusses response to screwworm outbreak concerns on 'The Claman Countdown.'
Elanco Animal Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 10% organic revenue growth, outpacing guidance, with strong performance across all segments and innovation products. Full-year guidance was raised for revenue, adjusted EBITDA, and EPS, while deleveraging continues and new retail and M&A initiatives expand reach.